Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya

Rachel C Vreeman, Winstone M Nyandiko, Hai Liu, Wanzhu Tu, Michael L Scanlon, James E Slaven, Samuel O Ayaya and Thomas S Inui

Abstract

Introduction: High levels of adherence to antiretroviral therapy (ART) are central to HIV management. The objective of this study was to compare multiple measures of adherence and investigate factors associated with adherence among HIV-infected children in western Kenya.

Methods: We evaluated ART adherence prospectively for six months among HIV-infected children aged ≤ 14 years attending a large outpatient HIV clinic in Kenya. Adherence was reported using caregiver report, plasma drug concentrations and Medication Event Monitoring Systems (MEMS®). Kappa statistics were used to compare adherence estimates with MEMS®. Logistic regression analyses were performed to assess the association between child, caregiver and household characteristics with dichotomized adherence (MEMS® adherence ≥ 90% vs. < 90%) and MEMS® treatment interruptions of ≥ 48 hours. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated.

Results: Among 191 children, mean age at baseline was 8.2 years and 55% were female. Median adherence by MEMS® was 96.3% and improved over the course of follow-up (p < 0.01), although 49.5% of children had at least one MEMS® treatment interruption of ≥ 48 hours. Adherence estimates were highest by caregiver report, and there was poor agreement between MEMS® and other adherence measures (Kappa statistics 0.04–0.37). In multivariable logistic regression, only caregiver-reported missed doses in the past 30 days (OR 1.25, 95% CI 1.05–1.49), late doses in the past seven days (OR 1.14, 95% CI 1.05–1.22) and caregiver-reported problems with getting the child to take ART (OR 1.10, 95% CI 1.01–1.20) were significantly associated with dichotomized MEMS® adherence. The caregivers reporting that ART made the child sick (OR 1.22, 95% CI 1.00–1.49) and reporting difficulties in the community that made giving ART more difficult (e.g. stigma) (OR 1.14, 95% CI 1.02–1.27) were significantly associated with MEMS® treatment interruptions in multivariable logistic regression.

Conclusions: Non-adherence in the form of missed and late doses, treatment interruptions of more than 48 hours and sub-therapeutic drug levels were common in this cohort. Adherence varied significantly by adherence measure, suggesting that additional validation of adherence measures is needed. Few factors were consistently associated with non-adherence or treatment interruptions.

Keywords: adherence; paediatric HIV; best practice; resource-limited setting.

To access the supplementary material to this article please see Supplementary Files under Article Tools online.

Introduction

The advent of antiretroviral therapy (ART) has significantly improved the long-term survival of HIV-infected children [1–5], and good outcomes rely on high rates of adherence to therapy [6–9]. The International Association of Physicians in AIDS Care recommends routine monitoring of adherence to ART for all patients in clinical settings to guide clinical decision making, prevent drug resistance, and evaluate adherence interventions, but there are no specific recommendations for monitoring adherence in paediatric HIV [10].

Recent studies suggest that children in low- and middle-income countries (LMICs) have similar or better rates of ART adherence compared to children from high-income countries; however, most estimates of paediatric adherence in LMICs come from heterogeneous and unvalidated measures [11–13]. Adherence assessment by caregiver reports is commonly used in studies reporting ART among children and is consistently higher than adherence by other measures like pill count or pharmacy refill, suggesting that caregivers likely overestimate their child’s adherence [12,13]. Electronic dose monitoring...
with technologies like Medication Event Monitoring Systems (MEMS™) – bottle caps fitted with a microchip that records the time and date of each bottle opening – is most consistently associated with virological outcomes [14,15] but is often too expensive for routine use in LMICs outside of research settings [16].

For children in LMICs who have limited access to second- and third-line treatment options, the preservation of first-line regimens through high rates of adherence is particularly important for survival into adolescence and adulthood [17,18]. Despite the importance of adherence to ART, children in LMICs often face multiple and complex barriers to achieving optimal adherence, and there are few data to inform adherence interventions [19]. A better understanding of factors that are associated with adherence in HIV-infected children is critical to the design and implementation of effective interventions.

The Academic Model Providing Access to Healthcare (AMPATH) provides comprehensive HIV care for over 5000 HIV-infected children (<15 years of age) on ART in western Kenya. We conducted a cohort study to describe adherence to ART among children in this setting. Our objective was twofold: 1) to describe adherence to ART using multiple measures and compare routine measures (e.g. caregiver-reported adherence) to MEMS™, and 2) investigate factors associated with poor adherence. This study adds to the literature on best practices for measuring adherence to ART among HIV-infected children in LMICs, and it may be used to inform adherence interventions in this population.

**Methods**

**Study design**

We conducted a prospective cohort study with 200 HIV-infected children, ≤14 years of age and on ART and their caregivers at AMPATH’s largest paediatric clinic, which is located at Moi Teaching and Referral Hospital (MTRH) in Eldoret – the fifth largest city in Kenya. Participants were followed for six months and participated in monthly study visits, which took place in a private room with study personnel. Study visits were scheduled on the same day as the child’s routine clinical visit; after the child was seen by their regular care provider, the child and caregiver would come to the research office for their study visit. Demographic and clinical characteristics were extracted by chart review. The study was approved by the Institutional Review Board at Indiana University School of Medicine in Indianapolis, Indiana, USA and by the Institutional Research and Ethics Committee at Moi University School of Medicine in Eldoret, Kenya.

**Setting**

AMPATH is a partnership between Moi University School of Medicine, MTRH and a consortium of North American academic medical centres led by Indiana University School of Medicine. AMPATH provides free ART (first- and second-line ART regimens only), primary care services and psychosocial and nutritional support for children and adults.

**Study participants**

A convenience sample of 200 caregiver-child dyads were identified by clinic and study personnel and referred for study participation. The target sample size for this study was selected to enable confident testing of up to 40 adherence questionnaire items, which is reported elsewhere. For psychometric analyses, at least five subjects per one item (with no fewer than 100 participants) are considered necessary for factor analysis [20]. Additionally, this sample size gave us adequate power to detect a beta coefficient of 0.4 at a 0.05 significance level under the conservative assumption of an error variance of 4 and independent variable standard deviation of 1.

Eligible children were HIV-infected, ≤14 years old, on either a nevirapine (NVP)- or efavirenz (EFV)-based first-line ART regimen and enrolled in care at the AMPATH paediatric outpatient clinic at MTRH. Fourteen was the maximum age limit for enrolment because children older than this age are routinely treated in the adult clinic. Enrolment was limited to children on first-line ART containing NVP or EFV because plasma drug concentrations were only available for these drugs, and NVP or EFV is part of the standard first-line paediatric regimen at AMPATH. The child’s current level of adherence was not considered for study referral or selection; however, it is possible that patients who had higher or lower levels of adherence would be more likely to enrol. “Caregiver” was defined as an individual who both accompanied the child to clinical and study visits and had knowledge of the child’s medication taking. While we encouraged the same caregiver to come to all assessments, we did not exclude different caregivers (e.g. mother versus grandfather) from participating in the study assessments. Informed consent was obtained for all caregivers, and assent for any child 10 years and older, in line with standard AMPATH research protocols. A small incentive was provided for participation to help cover transportation costs and time.

**Adherence measures**

Monthly adherence assessments included caregiver-reported adherence, drug concentrations and electronic medication monitoring using MEMS™ (AARDEX, Inc.). Caregiver-reported adherence was assessed through a 48-item questionnaire that included questions about missed or late doses, adherence barriers, household characteristics and a visual analogue scale (VAS) (adherence questionnaire provided under “Supplementary File”). VAS was used to assess the number of doses the child took over the last 30 days, with the caregivers indicating doses taken on a horizontal line; the rightmost side indicated that all doses were taken, and the leftmost side indicated no doses taken. A trained research assistant administered the questionnaire items verbally in Kiswahili or English (depending on the caregiver’s language preference) and then recorded the caregivers’ verbal responses on a paper form.

The patients’ NVP or EFV was kept in a bottle with a MEMS® cap for continuous electronic monitoring of medication dose timing throughout the study period. At enrolment, patients were informed of the purpose of the MEMS® cap and instructed in care of the cap and bottle. At each visit, study staff downloaded data from the MEMS® caps and shared these data with the caregivers and children by showing them the computer display with the record of dose timing.
using PowerView software (Version 3.5.2; AARDEX, Inc.). The downloading and sharing of dose timing from MEMS® were conducted after the administration of the adherence questionnaires at every visit. Replacement MEMS® were given to patients who reported damaged or lost MEMS®. MEMS® events that occurred during the study assessments (e.g. opening MEMS® to conduct pill counts) were censored for analyses.

NVP and EFV drug concentrations were taken at two time points (month 1 and month 4). Drug concentrations are not available routinely at AMPATH, but were run for study purposes in the AMPATH Reference Laboratory in Eldoret using a rapid, automated enzyme immunoassay developed by ARK Diagnostics (Sunnyvale, CA, USA). The ARK NVP-Test and ARK EFV-Test are based on competitive binding to antibody between the drug in the sample and a drug-labelled enzyme. Drug concentration was measured spectrophotometrically in terms of enzyme activity.

In the clinical care setting at AMPATH, the only routine adherence measure for children consists of clinicians asking either the caregiver or the child the following two questions: “During the last month, has the patient missed any medications?” and “During the last seven days, how many pills did the patient take?” These adherence data were extracted for study participants by chart review and compared to study-administered adherence measures.

Data analysis

Adherence by caregiver-reported missed doses and VAS adherence were dichotomized into “adherent” (defined as no indication of missed doses in the recall period) versus “non-adherent” (defined as any indication of missed doses) at each visit. Any indication of non-adherence was categorized as “non-adherent” because reports of non-adherence were so scarce using these measures and caregiver reports generally overestimate actual adherence [21]. Plasma drug concentrations were categorized into therapeutic levels: sub-therapeutic (NVP < 3.0 μg/mL or EFV < 1.0 μg/mL), therapeutic (NVP 3.0–7.6 μg/mL or EFV 1.0–4.0 μg/mL) or supra-therapeutic (NVP > 7.6 μg/mL or EFV > 4.0 μg/mL) [22,23]. Adherence by plasma drug concentration was dichotomized as “adherent” (defined as therapeutic or supra-therapeutic) versus “non-adherent” (defined as a sub-therapeutic range). For MEMS® adherence, mean and median adherence levels were calculated by visit and across visits to estimate the percentage of doses of NVP or EFV taken. MEMS® adherence was also dichotomized as “adherent” (defined as ≥90% of doses taken by MEMS®) versus “non-adherent” (defined as < 90% of doses taken). While we recognize that 90% adherence may not always be sufficient for viral suppression, MEMS® was dichotomized at above or below 90% adherence for consistency with previous studies [24,25]. Furthermore, studies show that below this level of adherence, the risks for HIV virological rebound and drug resistance are increased, particularly for older non-nucleoside reverse transcriptase inhibitors like EFV and NVP [26–28].

Univariable analyses with Student's t-tests and Pearson's chi-square tests were used to explore relationships between dichotomized MEMS® adherence and other adherence measures as well as demographic, clinical and psychosocial characteristics of the child and caregiver. Repeated-measures logistic regression analyses using odds ratios (ORs) and 95% confidence intervals (95% CIs) with and without adjusting for baseline characteristics (gender, age and duration on ART) were conducted using adherence data from each monthly visit. Due to the high correlation between caregiver-reported missed-doses variables using different recall periods (three-day, seven-day and 30-day), inclusion into the multivariable model was restricted to only one of these. The 30-day missed-dose variable was chosen as it had the smallest p-value in univariable models. We also used univariable and multivariable analyses (with and without adjusting for baseline characteristics, as above) to investigate factors associated with MEMS® treatment interruptions, defined as a single period of 48 hours or greater with no recorded bottle opening. Kappa statistics were calculated to compare adherence estimates by the different methods of measurement to MEMS®. We used MEMS® as the comparison adherence measure because it is commonly used as the reference standard in studies using multiple measures of adherence and best correlates with virologic outcomes [29–31]. All statistical analyses were performed using SAS Version 9.3 (SAS Institute, Cary, NC).

Results

Study participant characteristics

Among 191 caregiver-child dyads followed for six months, mean age of children at baseline was 8.2 years and 55% were female. Weight-for-age Z (WAZ) scores indicated mild malnutrition, with a mean WAZ score of −1.7. Mean duration on ART was 2.3 years, with most children on NVP-based regimens (77%). Children in this cohort had significant disease progression, with 54% at World Health Organization (WHO) Stage 3 at study start and a mean CD4 percentage of 26%. The most common type of caregiver participant was the biological mother of the child (63%), but there were also a number of father (11%) and grandparent (7%) participants. For the vast majority of children (90%), the same caregiver was present for all adherence assessments during the study period. Caregivers reported high levels of food insecurity (68%) and difficulties with transportation to clinic (84%). There were 17 participants (9%) who had to have their MEMS® replaced during the study period due to damage or MEMS® not functioning properly. In univariable analyses, there was no significant difference in baseline demographic and clinical factors between children who were always adherent during the study period (MEMS® adherence at every month ≥90%) and children who were non-adherent at least once (MEMS® adherence < 90% for at least one month) (Table 1).

Adherence by multiple measures

Mean adherence by MEMS® was 87% (median adherence by MEMS® was 96%) and improved significantly over the course of the study; while only 51% achieved MEMS® adherence ≥90% at month 1, 70% did so by month 6. Treatment interruptions were common; 49% of children had at least one MEMS® treatment interruption of ≥48 hours (with a median of 3 MEMS® treatment interruptions per child over the course of the study). Adherence by caregiver-reported missed
doses was higher using the three-day recall item (92% reported no missed doses) and seven-day recall (92% reported no missed doses) compared to the 30-day recall item (83% reported no missed doses). Caregivers reported even higher adherence by VAS (94% reported no missed doses). In contrast to MEMS™, caregiver-reported missed doses generally showed consistent or decreasing adherence across the study period (Figure 1). Fourteen per cent of children on NVP and 27% on EFV had sub-therapeutic drug levels, whereas 59% of children on NVP and 23% on EFV had supra-therapeutic drug levels (Table 2). Caregiver-reported missed doses to clinicians at routine clinic visits suggested the highest rates of adherence (97% reported no missed doses).

**Agreement between adherence measures**

There was poor agreement between dichotomized MEMS™ and other adherence measures, but most measures did show a statistically significant association with MEMS™ (Table 3).

**Table 1. Caregiver-child dyad characteristics by MEMS™ adherent group**

| Characteristic                              | Overall | Adherent (MEMS™ > 90% doses taken at every visit) | Ever non-adherent (MEMS™ < 90% doses taken at any visit) | p    |
|--------------------------------------------|---------|---------------------------------------------------|----------------------------------------------------------|------|
| Characteristic                             | N = 191 | N = 56                                            | N = 134                                                  |      |
| Child characteristics                       |         |                                                   |                                                          |      |
| Mean age (years)                           | 8.2 (3.3) | 8.3 (3.1)                                         | 8.1 (3.3)                                                | 0.70 |
| Female                                     | 105 (55%) | 29 (52%)                                          | 76 (57%)                                                 | 0.53 |
| Mean weight-for-age Z (WAZ) score          | −1.7 (1.3)* | −1.7 (1.2)                                      | −1.7 (1.3)                                               | 0.80 |
| Mean ART duration (years)                  | 2.3 (1.9) | 2.6 (1.8)                                         | 2.2 (1.8)                                                | 0.18 |
| ART regimen                                |         |                                                   |                                                          |      |
| NVP                                        | 148 (77%) | 47 (84%)                                          | 101 (74%)                                                | 0.26 |
| EFV                                        | 43 (22%)  | 9 (16%)                                           | 34 (25%)                                                 |      |
| NVP/EFV (both)                             | 2 (1%)   | 0 (0%)                                            | 2 (1%)                                                   |      |
| Mean CD4%                                   | 26% (11%) | 30% (9%)                                          | 25% (11%)                                                | 0.06 |
| WHO Stage                                  |         |                                                   |                                                          |      |
| 1                                          | 34 (18%)  | 11 (20%)                                          | 23 (17%)                                                 | 0.50 |
| 2                                          | 32 (17%)  | 11 (20%)                                          | 20 (15%)                                                 |      |
| 3                                          | 104 (54%) | 31 (55%)                                          | 75 (55%)                                                 |      |
| 4                                          | 18 (9%)   | 3 (5%)                                            | 15 (11%)                                                 |      |
| Not answered                               | 3 (2%)   | 0 (0%)                                            | 3 (2%)                                                   |      |
| Disclosure status                          |         |                                                   |                                                          |      |
| Child disclosed                            | 44 (23%) | 10 (18%)                                          | 34 (25%)                                                 | 0.26 |
| Caregiver and/or family characteristics     |         |                                                   |                                                          |      |
| Caregiver relationship to child            |         |                                                   |                                                          |      |
| Mother                                     | 121 (63%) | 32 (57%)                                          | 88 (66%)                                                 | 0.14 |
| Father                                     | 21 (11%)  | 7 (13%)                                           | 14 (10%)                                                 |      |
| Sibling                                    | 3 (2%)   | 0 (0%)                                            | 3 (2%)                                                   |      |
| Grandparent                                | 13 (7%)  | 3 (5%)                                            | 10 (7%)                                                  |      |
| Non-relative                               | 7 (4%)   | 5 (9%)                                            | 2 (1%)                                                   |      |
| Other                                      | 26 (14%) | 9 (16%)                                           | 17 (13%)                                                 |      |
| Individuals who give the child ART          |         |                                                   |                                                          |      |
| Mother                                     | 160 (84%) | 45 (80%)                                          | 114 (85%)                                                | 0.42 |
| Father                                     | 68 (36%)  | 21 (38%)                                          | 46 (34%)                                                 | 0.68 |
| Sibling                                    | 80 (42%)  | 18 (32%)                                          | 62 (46%)                                                 | 0.07 |
| Other relative                             | 68 (36%)  | 20 (36%)                                          | 48 (36%)                                                 | 0.98 |
| Child took own                              | 60 (31%)  | 13 (23%)                                          | 47 (35%)                                                 | 0.11 |
| Caregiver employed outside the home        | 99 (52%)  | 27 (49%)                                          | 72 (54%)                                                 | 0.56 |
| Enrolled in AMPATH nutrition programme      | 33 (17%) | 8 (14%)                                           | 24 (18%)                                                 | 0.54 |
| Food insecurity (reported “not enough food for family”) | 135 (68%) | 36 (64%)                                          | 98 (73%)                                                 | 0.22 |
| Reported difficulty with transportation to clinic | 159 (84%) | 44 (79%)                                          | 114 (86%)                                                | 0.23 |

*WHO classifies WAZ Score < −1 as “mild malnourishment”; rows do not sum to 100% because participants could report multiple persons who gave medicines.*
Among the study-administered measures, missed doses by seven-day recall (range of Kappa statistic: 0.11 to 0.34) and 30-day recall (range: 0.10 to 0.37) had highest agreement with the MEMS™. Missed doses by three-day recall (range: 0.05 to 0.25) had lower agreement with dichotomized MEMS™, and VAS even lower (range: 0.04 to 0.22). NVP (range: 0.15 to 0.24) and EFV (range: 0.20 to 0.36) drug concentration also showed poor agreement with MEMS™. Caregiver-reported missed doses of three-day, seven-day and 30-day recall significantly increased in agreement with MEMS™ from month 1 to month 2. Agreement was inconsistent thereafter, but generally remained higher than at month 1. Compared to other measures, the clinician-administered adherence items had the lowest agreement with MEMS™ and did not illustrate a significant improvement in agreement from month 1 to month 2 (range: 0.06 to 0.16). Simple binary correlation matrices between caregiver-reported missed doses revealed high correlations between adherence by different recall periods (three-day, seven-day, and 30-day), particularly for caregiver-reported missed doses in the past three days and in the past 30 days.

Predictors of adherence and treatment interruptions
In univariable analyses, factors associated with dichotomized MEMS™ adherence (Table 4) and treatment interruptions (Table 5) were reported by caregivers as: problems in the community, problems with giving the child medicines, medicines making the child sick, forgetting to give the medicines, giving late doses and missing doses. In repeated-measures logistic regression models, only caregiver-reported missed doses in the last 30 days (OR 1.25, 95% CI 1.14–1.39), late doses in the past seven days (OR 1.14, 95% CI 1.05–1.22) and caregiver-reported problems with getting the child to take ART (OR 1.10, 95% CI 1.01–1.20) were significantly associated with dichotomized MEMS™. Caregiver-reported difficulties related to community-level factors (OR 1.14, 95% CI 1.02–1.27) and medication side effects (OR 1.12, 95% CI 0.90–1.40) were not significantly associated with treatment interruptions.
1.01–1.25) were both significantly associated with treatment interruptions of ≥48 hours.

**Discussion**

In this cohort, adherence estimates by MEMS®, caregiver reports and plasma drug concentrations varied widely. MEMS® revealed high median rates of adherence (96% doses taken) for this cohort, but lower rates of mean adherence (87% of doses taken) and treatment interruptions were common. Caregiver-reported seven-day and 30-day recall of any missed doses to study personnel best correlated with MEMS® adherence, although no adherence measure showed good agreement with MEMS® and caregiver-reported missed doses to clinicians during routine clinic visits had the poorest agreement. Only the caregiver-reported problems with giving the child ART, medication side effects and difficulties related to community-level factors (particularly HIV-related stigma and discrimination) were significantly associated with MEMS® adherence. The relationship between caregiver-level HIV-related stigma and paediatric adherence deserves further

**Table 2. Adherence levels using multiple measures by visit**

| Adherence measure                                      | Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Composite |
|--------------------------------------------------------|---------|---------|---------|---------|---------|---------|-----------|
| MEMS® measures                                         |         |         |         |         |         |         |           |
| Mean MEMS® doses taken (SD)                            | 79% (26%) | 86% (21%) | 88% (19%) | 89% (18%) | 90% (19%) | 89% (18%) | 87%       |
| Median MEMS® doses taken (IQR)                         | 93% (73–96) | 96% (82–100) | 96% (89–100) | 96% (88–100) | 96% (87–100) | 96% (85–100) | 96%       |
| Dichotomized MEMS® (≥90% doses taken)                  | 51% | 64% | 67% | 67% | 68% | 68% | 68%       |
| Caregiver-reported measures                            |         |         |         |         |         |         |           |
| 3-day: missed doses (% no missed doses)                | 94% | 89% | 92% | 92% | 95% | 89% | 92%       |
| 7-day: missed at least one dose in a day (% no missed doses) | 85% | 85% | 81% | 86% | 85% | 79% | 84%       |
| 7-day: missed all doses in a day (% no missed doses)  | 90% | 92% | 93% | 94% | 94% | 91% | 92%       |
| 30-day: missed doses (% no missed doses)               | 75% | 74% | 73% | 72% | 74% | 73% | 74%       |
| Dichotomized VAS (% no missed morning doses)           | 96% | 91% | 95% | 94% | 93% | 91% | 93%       |
| Dichotomized VAS (% no missed evening doses)           | 99% | 99% | 93% | 96% | 92% | 91% | 95%       |
| Drug concentration measures                            |         |         |         |         |         |         |           |
| NVP plasma                                             |         |         |         |         |         |         |           |
| Sub-therapeutic                                        | 15% |         |         |         |         |         | n/a       |
| Optimal                                                | 34% |         |         |         |         |         | 66%       |
| Supra-therapeutic                                      | 51% |         |         |         |         |         |           |
| EFV plasma                                             |         |         |         |         |         |         |           |
| Sub-therapeutic                                        | 21% |         |         |         |         |         | n/a       |
| Optimal                                                | 55% |         |         |         |         |         | 46%       |
| Supra-therapeutic                                      | 24% |         |         |         |         |         |           |
| Routine AMPATH adherence                               |         |         |         |         |         |         |           |
| AMPATH Clinical Encounter Form (% no missed doses in past 30 days) | 98% | 96% | 95% | 99% | 96% | 96% | 97%       |

**Table 3. Agreement between multiple measures and dichotomized MEMS®**

| Kappa statistics |
|------------------|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 |
| 3-day recall     | 0.05   | 0.25** | 0.14*  | 0.14*  | 0.12*  | 0.23*  |
| 7-day recall     | 0.11   | 0.29** | 0.21*  | 0.24** | 0.34** | 0.29** |
| 30-day recall    | 0.10   | 0.33** | 0.36** | 0.28** | 0.37** | 0.30** |
| VAS              | 0.10   | 0.21   | 0.22*  | 0.08   | 0.04   | 0.20*  |
| NVP drug concen. | 0.15*  |        |        | 0.24** |        |        |
| EFV drug concen. | 0.36** |        |        | 0.20   |        |        |
| AMPATH clinical encounter form | 0.11* | 0.13* | 0.12* | 0.06 | 0.16* | 0.12* |

*p < 0.05; **p ≤ 0.001.
Table 4. Items associated with dichotomized MEMS© non-adherence

| Caregiver-reported factors                                                                 | Univariable model | Multivariable model* |
|-------------------------------------------------------------------------------------------|-------------------|----------------------|
| Forgot to keep time when giving the medicines                                              | 1.07 (1.02–1.14)  | 1.05 (0.99–1.11)     |
| Problems getting the child to take the medicines                                           | 1.15 (1.05–1.26)  | 1.09 (1.01–1.20)     |
| Problems giving the child medicine because the child does not know reason for medicines. (i.e. child does not know HIV status) | 1.18 (1.02–1.37)  | 1.13 (0.97–1.32)     |
| Missed doses in past 3 days                                                                | 1.19 (1.07–1.32)  | 0.93 (0.81–1.06)     |
| Missed doses in past 30 days                                                               | 1.27 (1.17–1.39)  | 1.22 (1.09–1.38)     |
| Missed all doses in a day in past 7 days                                                   | 1.15 (1.04–1.25)  | 1.00 (0.87–1.15)     |
| Missed one dose in a day in past 7 days                                                    | 1.21 (1.11–1.32)  | 1.10 (0.97–1.24)     |
| Took a dose more than one hour late in past 7 days                                        | 1.19 (1.10–1.28)  | 1.13 (1.06–1.22)     |

*Multivariable models adjusted for baseline gender, age (years) and duration on ART (years).

investigation, as a large study among African adults found that individuals who reported more perceived HIV stigma were more likely to report non-adherence to therapy [32]

Caregiver report is one of the most commonly used adherence assessment methods for HIV-infected children in resource-limited settings, but it likely overestimates adherence to ART compared to other, more objective measures like pill counts, pharmacy refill and electronic dose monitoring [13]. We also found caregiver-reported adherence to be significantly higher than adherence by MEMS©, and there was generally poor agreement between caregiver-reported missed doses and MEMS©. Our findings are consistent with work in Zambia that found relatively poor agreement between MEMS© and other adherence measures like caregiver-reported missed doses, VAS and pill counts [33]. Other studies also suggest that caregiver reports overestimate their child’s adherence to ART and are not a valid adherence assessment strategy [34–37].

The longitudinal nature of this study allowed us to detect changes in adherence. We found significantly improved MEMS© adherence from month 1 to month 2, which was sustained over the course of the study and is consistent with a similar study in Zambia [33]. Our study was not designed to measure an intervention effect, but the significant change suggests that some aspect of the study procedures may have improved adherence in this cohort. Further work is needed to evaluate individual components of the study procedures (e.g. discussing adherence and barriers with study staff, reviewing MEMS© feedback, having medications in bottles with MEMS© etc.) as an adherence intervention. Using feedback from MEMS© as part of adherence counselling has been shown to be effective in improving adherence in randomized controlled trials among adults living with HIV [38,39]; however, there are few data available for children. Caregivers generally reported more missed doses to study personnel after month 1, despite significantly higher MEMS© adherence. This may suggest that caregivers became more comfortable reporting non-adherence to study personnel over time or that the use of MEMS© feedback encouraged more reporting of non-adherence because caregivers knew that the study team could see the number and timing of missed doses by MEMS©. We hypothesize that the caregiver-reported adherence to study staff became less biased and more accurate as the study progressed. This trend was not evident in caregiver-reported missed doses to clinicians, suggesting that adherence assessments outside the patient-provider relationship (e.g. using adherence counsellors or case managers) may yield more accurate reporting of non-adherence for children.

The frequent treatment interruptions of ≥48 hours in this cohort were concerning as interruptions increase risks of drug resistance and viral rebound [40–42]. Unplanned
treatment interruptions may be more likely in LMICs due to barriers like inconsistent drug supplies, the financial costs of drugs and transportation to clinic, food insecurity and HIV stigma [19]. AMPATH did not have any major pharmacy stock-outs during the study period; however, malnutrition and poverty were high in this cohort. Previous qualitative work among caregivers of HIV-infected children in this setting suggested that HIV stigma and HIV disclosure pose significant challenges to ART adherence [43]. The association between caregiver-reported community-level factors (e.g. stigma) and treatment interruptions in this study supports the idea that social factors impact adherence. Children's knowledge of their own HIV status may impact adherence, but we did not find a significant association between disclosure and adherence. At least 25% of caregivers reported giving a late dose in the past week at monthly visits, but late doses were not associated with treatment interruptions, suggesting that different factors may affect interruptions versus delays. For example, in previous qualitative work in this setting, we found that children experience treatment interruptions when traveling over the weekend, whereas delays are experienced when caregivers arrive home late at night from work or visitors are in the home [43].

Collecting plasma drug concentrations was a unique aspect of this study and is not often available in this setting. We found that significant numbers of children had sub-therapeutic and supra-therapeutic drug levels. This is concerning as sub-therapeutic levels are associated with drug resistance and virologic failure, while supra-therapeutic levels are associated with increased frequency and severity of side effects in adults living with HIV [44–48]. Children on EFV were more likely to have sub-therapeutic levels than children on NVP, whereas children on NVP were more likely to have supra-therapeutic levels; in fact, more than half of children on NVP had supra-therapeutic drug levels. Drug concentrations did not correlate well with MEMS™ adherence, which may be due to several factors. First, MEMS™ adherence was calculated for all doses taken between study visits (approximately one month), whereas drug concentrations only indicate adherence within hours to days. Drug concentrations would likely correlate better with MEMS™ if MEMS™ were restricted to doses taken in the 2-3 days prior. Second, drug concentrations may be influenced by the dearth of pharmacokinetic data for antiretroviral drugs in children, especially in sub-Saharan Africa [49,50]. AMPATH follows standard paediatric dosing recommendations, but it is possible that these dosing guidelines are not optimal and lead to sub-therapeutic or supra-therapeutic drug concentrations, even if the patient is adherent. Inappropriate drug levels may reflect problems with dosing recommendations more than adherence difficulties. A study among children on EFV-based regimens in South Africa found that 40% had sub-therapeutic drug levels (<1.0 μg/mL), while another study in South Africa reported median sub-therapeutic levels of EFV in 17% of children at one, three and six months of follow-up [51,52]. The proportion of children in our cohort with supra-therapeutic drug levels also deserves further consideration, particularly because caregiver-reported medication side effects were significantly associated with treatment interruptions. Studies in Malawi, Zambia and Germany have reported high rates of supra-therapeutic drug levels in children, although not as high as those found in our study [53,54]. More pharmacokinetic studies among African paediatric populations are needed to ensure that dosing recommendations are appropriate.

Several limitations of this study deserve consideration. First, this study employed convenience sampling that introduces potential selection bias and, in this case, might have led to children who had excellent adherence or very low adherence being more likely to enrol. Regardless of baseline adherence levels and whether they were higher or lower than those of the general AMPATH paediatric population, we still should have been able to detect significant associations between adherence and various clinical, demographic and social factors. Second, the intensive study procedures likely affected adherence over the course of the study; however, we could not evaluate these effects. Third, electronic drug monitoring is typically reserved for research settings, as the technology is too expensive for routine monitoring. Furthermore, MEMS™ has important limitations (e.g. patients removing more than one dose of medicines or switching between bottles) that have not been adequately explored in this setting [55,56]. Fourth, we did not have access to viral load testing for this cohort of patients. Virologic suppression is considered the most important outcome of adherence to therapy [57]; however, due to funding constraints, viral loads were unavailable. Finally, our sample of 191 children was relatively small, and follow-up time was relatively short. Children were on first-line ART for a mean of 2.3 years and most were entering early adolescence, so issues of treatment fatigue and disclosure of HIV status may present additional barriers to adherence in the coming years [58]. Furthermore, this study took place at the largest, most urban clinic within AMPATH, and so our findings may not be generalizable for smaller or more rural clinics. Nonetheless, this sample provides detailed adherence measurements for a sub-Saharan African paediatric population and provides preliminary support for validating routine adherence monitoring in paediatric populations in LMICs, as well as pointing to electronic monitoring with feedback as a potential adherence intervention.

Conclusions

We found that caregiver-reported missed doses overestimate children's adherence to ART compared to electronic dose monitoring. Despite high rates of adherence by caregiver report, missed and late doses, treatment interruptions of more than 48 hours and sub-therapeutic drug levels were common.

Authors’ affiliations

1Children’s Health Services Research, Department of Pediatrics, Indiana University School of Medicine Indianapolis, IN, USA; 2Academic Model Providing Access to Healthcare (AMPRH), Eldoret, Kenya; 3Regenstrief Institute, Inc., Indianapolis, IN, USA; 4Department of Child Health and Paediatrics, Moi University School of Medicine, Eldoret, Kenya; 5Department of Biostatistics, Indiana University School of Medicine Indianapolis, IN, USA; 6Department of Medicine, Indiana University School of Medicine Indianapolis, IN, USA

Competing interests

The authors declare that they have no competing interests.
Authors’ contributions
RCV and WMN conceptualized and designed the study, oversaw statistical analyses and interpretation of results, and led the drafting of the manuscript. HL and WT contributed to the design of the study, led statistical analyses and interpretation of results, and contributed to the drafting of the initial manuscript. MLS contributed significantly to carrying out study procedures, including coordination and supervision of data acquisition and interpretation of results, and to the drafting of the initial manuscript. JES contributed significantly to the cleaning of data, statistical analyses and the drafting of the initial manuscript. SOA and TSI contributed significantly to the initial conception and design of the study as well as to the critical review of the manuscript. All authors have read and approved the final manuscript as submitted.

Acknowledgements
We would first and foremost like to thank the Kenyan families who took part in this study. We would also like to acknowledge the significant work of key clinicians and nurses at AMPATH in promoting and helping evaluate adherence, including Irene Marete, Edith Apondi, Peter Gisore, Constance Tenge, John Chumba, Esther Nabakwe, Lucy Warui, Mary Rugut, Victor Cheboi and Christine Mukhwana.

Funding
This research was supported in part by a grant (1K23MH087225) to Dr Vreeman from the US National Institute of Mental Health and AMPATH Plus with support from the United States Agency for International Development as part of the President’s Emergency Plan for AIDS Relief (PEPFAR).

Disclaimer
The views expressed in this article are those of the authors and do not necessarily represent the view of the Indiana University School of Medicine or the Moi University School of Medicine. The authors have no conflicts of interest to disclose. The primary author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References
1. World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access – progress report 2011. Geneva: World Health Organization; 2011.
2. Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, et al. Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J. 2006;25(5):420–6.
3. Gild MD, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, et al. Decline in mortality, AIDS, and HIV-related admissions in perinatally HIV-1-infected children in the United Kingdom and Ireland. BMJ. 2003;327(7422):1019.
4. Hogg RS, Heath KV, Yip B, Craib KJ, O’Sullivan MV, Sabin CA, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450–4.
5. Needham DM, Hogg RS, Yip B, Sabin CA, O’Sullivan MV, Sabin CA, et al. The impact of antiretroviral therapy on AIDS survival observed in a province-wide drug treatment programme. Int J STD AIDS. 1998;9(6):370–2.
6. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.
7. Garcia de Olalla P, Knobel H, Carmona-A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(1):105–10.
8. Gavin PI, Voge R. The role of protease inhibitor therapy in children with HIV infection. Paediatr Drugs. 2002;4(9):581–607.
9. Gild MD, Gild MD, Lodding RL, Giacometi V, McClellan M, Compagnucci A, Lyall H. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA S trial. Pediatr Infect Dis J. 2003;22(1):56–62.
10. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817–33, W-284, W-5, W-6, W-7, W-8, W-9, W-90, W-91, W-92, W-93, W-94.
11. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S49–55.
12. Vreeman RC, Nyandiko WM, Blaschke TF. Adherence to antiretroviral therapy for adults and children in resource-limited settings. Rev Antirheur Ther. 2006;2(5):S6–13.
13. Vreeman RC, Wiehe SE, Pearce EC, Nyandiko WM. A systematic review of pediatric adherence to antiretroviral therapy in low- and middle-income countries. Pediatr Infect Dis J. 2008;27(8):868–91.
14. Hogan PW, Lannebeck N, Burger DM, Zomer B, van Leusen R, Schuurman R, et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr. 2002;30(3):324–34.
15. Walsh K, Mandaliya S, Gazzard B. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16(2):269–77.
16. Muller AD, Jaspan HB, Myer L, Hunter AL, Harling G, Bekker LG, et al. Standard measures are inadequate to monitor pediatric adherence in a resource-limited setting. AIDS Behav. 2011;15(2):422–31.
17. Ford N, Wilson D, Costa Chaves G, Lotrotswka M, Kijjwatwachaluk K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS. 2007;21(Suppl 4):S21–9.
18. Zyl GU, Rabe B, Nutall JJ, Cotton MF. It is time to consider third-line options in antiretroviral-experienced paediatric patients? J Int AIDS Soc. 2011;14:55.
19. Scanlon ML, Vreeman RC. Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings. HIV AIDS (Auckl). 2013;5:1–7.
20. Gorsuch RL. Factor analyses. 2nd ed. Hillsdale, NJ: Erlbaum; 1983.
21. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics. 2007;119(6):e1371–83.
22. Porte CJ, Bick D, Blaschke T, Boucher CA, Fletcher CV, Flemer C, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antirheur Ther. 2006;3:14–4.
23. Leth KV, Kappelhoff BS, Johnson D, Losso MH, Boron-Kaczmarska A, Saag MS, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses. 2006;22(3):232–9.
24. Haberer JE, Kiwanuka J, Nansera D, Ragland K, Mellins C, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PloS One. 2012;7(5):e36737.
25. Bangsberg D, de Hecht FM, Charlebois ED, Chenrey M, Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic Medication Monitors and unannounced pill counts. AIDS Behav. 2001;5(3):275–81.
26. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53(5):687–9.
27. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37(8):1112–8.
28. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.
29. Deschamps AE, De Geest S, Vandamme AM, van Wijngaerden E. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDS. 2006;20(9):743–45.
30. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.
31. Arnsten JH, Demas PA, Farazdekan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in antiretroviral-experienced pediatric patients: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–23.
32. Diamini PS, Wantland D, Makoae LN, Chirwa M, Koli TW, Greeff M, et al. HIV stigma and missed medications in HIV-positive people in five African countries. AIDS Patient Care STDS. 2009;23(5):377–87.
33. Haberer JE, Cook A, Walker AS, Ngambi M, Ferrier A, Mulenga V, et al. Excellent adherence to antiretrovirals in HIV+ Zambian children is compro-
mised by disrupted routine, HIV nondisclosure, and paradoxical income effects.

PloS One. 2011;6(4):e18505.

34. Farley J, Hines S, Musk A, Ferrus S, Tepper V. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr. 2003;33(2):211–8.

35. Reddington C, Cohen J, Baldillo A, Toye M, Smith D, Kneut C, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2000;19(12):1148–53.

36. Steele RG, Anderson B, Rindel B, Dreyer ML, Perrin K, Christensen R, et al. Adherence to antiretroviral therapy among HIV-positive children: examination of the role of caregiver health beliefs. AIDS Care. 2001;13(5):617–29.

37. Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109(4):e61.

38. Sabin LL, DeSilia MB, Hamer DH, Xu K, Zhang J, Li T, et al. Using electronic drug monitor feedback to improve adherence to antiretroviral therapy among HIV-positive patients in China. AIDS Behav. 2010;14(3):580–9.

39. de Bruin M, Hospers HJ, van Breukelen GJ, Kok G, Koevoets WM, Prins JM. Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: a randomized controlled trial. Health Psychol. 2010;29(4):421–8.

40. Ouygi JH, Byakika-Tusime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21(8):965–71.

41. Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, et al. Response to antiretroviral therapy in HIV-infected patients attending a public urban clinic in Kampala, Uganda. Clin Infect Dis. 2006;42(2):252–9.

42. Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Acquir Immune Defic Syndr. 2007;45(2):133–6.

43. Vreeman RC, Nyandiko WM, Ayapa SO, Walumbe EG, Marrero DG, Inui TS. Factors sustaining pediatric adherence to antiretroviral therapy in western Kenya. Qual Health Res. 2009;19(12):1716–29.

44. Veldkamp AI, Weaverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15(9):1089–95.

45. de Vries-Sluijs TE, Dielemann JP, Arts D, Huitema AD, Beijnen JH, Schutten M, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinetics. 2003;42(6):599–605.

46. Marzolini C, Teleni D, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(1):71–5.

47. Csaicsz A, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Teleni A, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003;73(1):20–30.

48. Stahlé L, Moberg I, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit. 2004;26(3):267–70.

49. Frajul PJ, van Kampen JJ, Burger DM, de Groot R. Pharmacokinetics of antiretroviral therapy in HIV-1-infected children. Clin Pharmacokinetics. 2005;44(9):935–56.

50. Fraijul PL, Rahmanina N, Burger DM, de Groot R. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit. 2004;26(2):122–6.

51. Ren Y, Nuttall JJ, Ebbers C, Eley BS, Meyers TM, Smith PJ, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr. 2007;45(2):133–6.

52. Viljoen M, Gous H, Kruger HS, Riddick A, Meyers TM, Rheeders M. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. AIDS Res Hum Retroviruses. 2010;26(6):613–9.

53. Ellis JC, L’Homme RF, Ewins FM, Mulenga V, Bell F, Chileshe R, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther. 2007;12(2):253–60.

54. Wintergerst U, Hoffmann F, Janssen A, Notheis G, Husz K, Kurowkii M, et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother. 2008;61(6):1336–9.

55. Bova CA, Fennennie KP, Knafi GJ, Dieckhaus KD, Watrous E, Williams AB. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav. 2005;9(1):103–10.

56. Wendel CS, Mohler MJ, Kroesen K, Ample NM, Gifford AL, Coons SJ. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35(9):1010–5.

57. Martin M, Del Cacho E, Codina C, Tuset M, De La Cueva R, Mallolas J, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24(10):1263–8.

58. Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2005;2(4):184–200.